KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Non-Current Debt (2017 - 2025)

Amneal Pharmaceuticals has reported Non-Current Debt over the past 9 years, most recently at $2.6 billion for Q4 2025.

  • Quarterly results put Non-Current Debt at $2.6 billion for Q4 2025, up 18.66% from a year ago — trailing twelve months through Dec 2025 was $2.6 billion (up 18.66% YoY), and the annual figure for FY2025 was $2.6 billion, up 18.66%.
  • Non-Current Debt for Q4 2025 was $2.6 billion at Amneal Pharmaceuticals, roughly flat from $2.6 billion in the prior quarter.
  • Over the last five years, Non-Current Debt for AMRX hit a ceiling of $2.7 billion in Q2 2021 and a floor of $36.8 million in Q1 2021.
  • Median Non-Current Debt over the past 5 years was $2.3 billion (2024), compared with a mean of $1.8 billion.
  • Peak annual rise in Non-Current Debt hit 6828.74% in 2022, while the deepest fall reached 98.57% in 2022.
  • Amneal Pharmaceuticals' Non-Current Debt stood at $38.0 million in 2021, then soared by 6714.19% to $2.6 billion in 2022, then decreased by 7.95% to $2.4 billion in 2023, then fell by 9.4% to $2.2 billion in 2024, then rose by 18.66% to $2.6 billion in 2025.
  • The last three reported values for Non-Current Debt were $2.6 billion (Q4 2025), $2.6 billion (Q3 2025), and $2.1 billion (Q2 2025) per Business Quant data.